We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
~The product will be available under the brand name ‘Ledifos’ in India~
India, Hyderabad, 3rd August 2015: Hetero group, one of India’s leading generic pharmaceutical companies and one of the world’s largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar ‘Rituximab’ under the brand name MABALLTM’ in India. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero.
The launch of biosimilar Rituximab will provide a much needed access to patients in India suffering with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.
Commenting on the launch of the product, Dr Bandi Parthasaradhi Reddy, CMD, Hetero Group said: “The launch of MABALL strengthens Hetero’s position in the Biosimilar market, and has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (MAB’s).”
He further added, “Biosimilars is one of the key strategic business areas for Hetero. We have invested in biosimilars and will introduce more biosimilar MAB’s in the future. We also have plans to introduce affordable biosimilar Rituximab into key markets outside India through our partners”
Hetero’s Rituximab is a Biosimilar version of Roche’s Rituximab. Rituximab is a monoclonal antibody used alone or with other drugs to treat non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. It is also used for the treatment of other indications such as Rheumatoid Arthritis
About Hetero
Hetero is one of India’s leading generic pharmaceutical companies and is one of the world’s largest global producer of anti-retroviral drugs for the treatment of HIV/AIDS. Established by Dr. B.P.S. Reddy in 1993, Hetero is in the business of development, manufacturing and marketing of drug intermediates, active pharmaceutical ingredients (APIs), and finished dosages. Hetero is the largest privately-held pharmaceutical company and is one of the top 10 pharmaceutical companies in India with an annual turnover of US $1.2 billion. Hetero has over 25 state-of-the-art manufacturing facilities which has been approved by various regulatory authorities like US FDA, EU, WHO etc. With over 200 products in its portfolio across various therapeutic areas, Hetero has a strong global presence in over 120 countries and focuses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com.
Media Contact:
Jeyasingh Balakrishnan Head – Corporate Communications Hetero Labs Limited, India Mobile: +91 9989626541/ +91 9833836185 Email: Jeyasingh.b@heterodrugs.com